Artelo Biosciences (ARTL) Stock Statistics & Valuation Metrics

Artelo Biosciences has a market cap or net worth of $2.13M. The enterprise value is $6.43M.

Artelo Biosciences has 1,145,635 shares outstanding. The number of shares has decreased by -2.65% in one year.

Artelo Biosciences’s return on equity (ROE) is -3.44 and return on invested capital (ROIC) is -341.37%.

The current PE Ratio of Artelo Biosciences is ―. Artelo Biosciences’s PEG ratio is 0.73.

In the last 12 months, Artelo Biosciences had revenue of 0.00 and earned -9.83M in profits. Earnings per share was -3.05.

In the last 12 months, operating cash flow was -6.65M and capital expenditures 0.00, giving a free cash flow of -6.65M billion.

Artelo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Artelo Biosciences upcoming earnings date is Apr 1, 2026, TBA (Confirmed).

Artelo Biosciences as a current ratio of 1.44, with Debt / Equity ratio of -62.45%

In the past 12 months, Artelo Biosciences has paid 0.00 in taxes.

Artelo Biosciences EV to EBITDA ratio is -1.81, with an EV/FCF ratio of -2.19.

Artelo Biosciences has $2.07M in cash and marketable securities with $878.00K in debt, giving a net cash position of $1.19M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Artelo Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is Hold